Amicus Therapeutics, Inc. : Amicus Therapeutics Appoints Bradley L. Campbell as Chief Business Officer

CRANBURY, N.J., Jan. 23, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the promotion of Bradley L. Campbell to the new position of Chief Business Officer.

Mr. Campbell has over a decade of experience in the rare and orphan disease field. He joined Amicus in 2006 and has assumed positions of increasing responsibility, most recently serving as Senior Vice President, Business Operations. In his new role, Mr. Campbell will remain the head of several departments including Business Development, Program Management, Commercial Planning, and Patient Advocacy, and has added responsibility for Technical Operations as well as increased participation in Investor Relations. He will continue to report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.

Mr. Crowley stated, "On behalf of our board of directors and executive team, I am most pleased to announce Bradley's promotion to Chief Business Officer, in recognition of his operational expertise and leadership here at Amicus and more broadly within our industry and the rare disease community. His commercial experience in the orphan space is also critical to Amicus as we support GSK's marketing strategy for migalastat, and continue to advance our proprietary chaperone pipeline."

Prior to joining Amicus, Mr. Campbell worked at Genzyme Corporation in various roles in marketing, commercial planning and business development. His previous experience also includes positions in sales and marketing, and strategy and operations for Bristol-Myers Squibb, as well as strategy consulting for Marakon Associates.

Mr. Campbell received his B.A. in Public Policy from Duke University and his M.B.A. from Harvard Business School. He is active in various philanthropic organizations, and currently sits on the Executive Committee of the Board of the National Tay-Sachs and Allied Diseases Association.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.

FOLD-G

CONTACT: Investors/Media:

         Sara Pellegrino

         [e-mail]

         [phone]

Source: Amicus Therapeutics, Inc.

News Provided by Acquire Media